Company intelligence / Profile preview

Ryne Biotechnology

San Diego, California, United States

Ownership: Private
Development stage: Other

Overview

RNDP-001 has completed preclinical efficacy and safety studies; advancing toward IND submission for Phase 1 trials in Parkinson’s disease with CIRM funding

Therapeutic areas: Neurology
Modalities: Cell therapyiPSC-derived neuron replacement therapy
Industry: Biotech

Partnerships

California Institute for Regenerative Medicine (CIRM)

Beyond the preview

Go deeper on Ryne Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ryne Biotechnology.

Explore the full profile